AngioDynamics Inc

Healthcare · Medical Instruments & Supplies

15.50$ +1.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

AngioDynamics Inc (ANGO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 87 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ANGO
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	88	89	86	87	85	87	84	88	85	92	86	96	66	70	70	58	70	73	71	77	77	78	74	87	82	85	81	91	79	79	75	71	67	73	72	80	76	79	78	87	320
Cost of Revenue	43	44	42	45	44	44	38	41	28	29	27	-8.3	28	28	29	28	34	33	33	35	37	38	35	41	39	40	40	45	39	39	39	32	31	33	33	38	34	37	37	37	145
Gross Profit	45	45	44	42	41	43	45	47	36	41	38	16	38	42	40	30	36	40	39	42	40	41	39	46	42	45	41	46	40	40	36	39	37	40	39	42	42	42	41	49	175
Research & Development	6.7	5.9	6.0	6.7	6.4	6.1	6.5	6.5	7.7	7.4	7.2	7.2	6.3	7.8	8.4	7.2	9.0	9.7	8.6	9.1	7.4	8.2	7.3	7.9	8.3	6.8	6.9	7.9	7.9	8.7	8.2	6.7	6.3	6.4	6.9	6.6	6.4	7.8	7.1	8.2	29
Selling, General & Administrative	8.2	7.8	7.0	8.3	8.1	7.5	7.7	7.9	8.5	9.3	8.8	8.6	8.5	11	10	8.2	8.6	9.2	9.0	9.1	8.9	9.7	8.7	11	10	11	8.8	10	11	9.3	11	10	11	10	10	10	13	10	11	10	44
Total Operating Expenses	41	29	39	54	41	42	41	43	42	43	42	32	39	45	47	187	41	45	42	64	48	49	44	53	56	53	49	67	5.0	53	236	53	50	51	49	48	53	45	48	70	215
Operating Income	3.6	16	5.1	-11	0.1	1.1	4.9	4.4	-6.1	-2.5	-3.7	-16	-0.8	-3.4	-6.2	-157	-5.1	-4.8	-3.7	-22	-8.1	-8.7	-5.3	-6.4	-13	-8.1	-8.9	-21	35	-13	-200	-14	-13	-11	-10.0	-5.8	-11	-2.5	-6.4	-20	-40
Interest Expense	0.7	0.8	0.6	0.7	0.7	0.8	0.7	0.8	0.9	1.3	1.4	1.4	0.5	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4	0.7	0.7	0.9	0.1	0.5	0.4	0.6	–	–	–	–	0.0	0.1	0.1	0.1	0.3
Pre-Tax Income	2.9	14	4.6	-12	0.0	0.1	4.1	3.3	-6.9	-3.8	-5.4	-18	-1.4	-3.3	-6.5	-157	-4.8	-5.2	-4.1	-22	-8.6	-8.9	-5.8	-6.7	-14	-9.1	-9.7	-22	35	-13	-200	-14	-13	-11	-4.4	-6.1	-11	-6.4	-8.1	-11	-36
Income Tax Expense	1.6	0.7	1.7	0.9	0.0	-0.2	-9.9	1.2	-1.2	-0.2	-0.8	-4.4	-0.1	-0.6	-0.8	0.2	-0.5	-0.9	-0.6	-2.5	-1.6	-0.5	-0.8	-0.5	-0.9	-0.6	-0.2	-0.4	-11	16	-12	-0.7	0.1	-0.1	0.0	-0.1	0.1	0.0	0.0	0.4	0.4
Net Income	1.3	14	2.9	-13	0.0	0.2	14	2.1	-0.5	2.1	0.8	-14	-1.3	-2.7	-5.7	-157	-4.3	-4.3	-3.5	-19	-7.0	-8.4	-5.0	-6.3	-13	-8.5	-9.5	-21	46	-29	-188	-13	-13	-11	-4.4	-6.1	-11	-6.4	-8.1	-11	-37
EBITDA	9.8	21	11	-5.0	6.5	6.7	11	9.9	-0.4	4.2	2.9	-9.9	4.3	2.6	0.1	-150	2.0	1.5	2.5	-15	-1.5	-1.4	1.8	1.1	-5.8	4.4	2.5	-13	-3.0	0.0	-4.1	1.0	-1.9	1.8	-0.3	2.2	-4.8	-0.4	-2.4	-28	-36

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings